Huangheng Tao

Dr. Huangheng Tao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TLTao Liu
Tao Liu
SWSanyun Wu
Sanyun Wu
HTHuangheng Tao
Huangheng Tao
GZguang zeng
guang zeng
FZFuling Zhou
Fuling Zhou
XWXinghuan Wang
Xinghuan Wang
Background: It is to be determined whether people infected with SARS-CoV-2 will develop long-term immunity against SARS-CoV-2 and retain long-lasting protective antibodies after the infection is resolved. This study was to explore to explore the outcomes of IgG antibodies to SARS-CoV-2 in four groups of individuals in Wuhan, China. Methods: We included the following four groups of individuals who received both COVID-19 IgM/IgG tests and RT-PCR tests for SARS-CoV-2 from February 29, 2020 to April 29, 2020: 1470 hospitalized patients with COVID-19 from Leishenshan Hospital, Zhongnan Hospital of Wuhan University, and Wuhan No. 7 Hospital, 3832 healthcare providers without COVID-19 diagnosis, 19555 general workers, and 1616 other patients to be admitted to the hospital (N=26473). COVID-19 patients who received IgM/IgG tests <21 days after symptom onset were excluded. Results: IgG prevalence was 89.8% (95% CI 88.2-91.3%) in COVID-19 patients, 4.0% (95% CI 3.4-4.7%) in healthcare providers, 4.6 (95% CI 4.3-4.9 %) in general workers, and 1.0% in other patients (p all <0.001 for comparisons with COVID-19 patients). IgG prevalence increased significantly by age among healthcare workers and general workers. Prevalence of IgM antibodies to SARS-CoV-2 was 31.4% in COVID-19 patients, 1.5% in healthcare providers, 1.3% in general workers, and 0.2% in other patients. Conclusions: Very few healthcare providers had IgG antibodies to SARS-CoV-2, though a significant proportion of them had been infected with the virus. After SARS-CoV-2 infection, people are unlikely to produce long-lasting protective antibodies against this virus. Primary Funding Sources: Part of the study was supported by National Key Research and Development Program of China (2020YFC0845500). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors. Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. Data and code availability statement: Data and analyses codes are available from the corresponding authors on request. All request for raw and analyzed data and materials will be reviewed by the corresponding authors to verify whether the request is subject to any intellectual property or confidentiality obligations. Access will be granted after a signed data access agreement is attained.

24 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HYHua Yu
Hua Yu
LCLiang Chen
Liang Chen
XWXia Wang
Xia Wang
FTFeng Tang
Feng Tang
ZWZiyu Wan
Ziyu Wan
JPJianping Peng
Jianping Peng
SCL/TAL1 interrupting locus (STIL) regulates centriole replication and causes chromosome instability, which is closely related to malignant tumors. The purpose of our study was to investigate the role of STIL in bladder cancer (BC) tumorigenesis for the first time. The public database indicated that STIL is highly expressed and correlated with the cell cycle in BC. Immunohistochemistry staining showed that STIL expression is significantly elevated in BC tissues compared with paracancer tissues. CRISPR-Cas9 gene editing technology was used to induce BC cells to express STIL-specific sgRNA, revealing a significantly delayed growth rate in STIL knockout BC cells. Moreover, cell cycle arrest in the G0/G1 phase was triggered by decreasing STIL, which led to delayed BC cell growth in vitro and in vivo. Mechanically, STIL knockout inhibited the PI3K/AKT/mTOR pathway and down-regulated the expression of c-myc. Furthermore, SC79 (AKT activating agent) partially reversed the inhibitory effects of STIL knockout on the proliferation and migration of BC cells. In conclusion, STIL enhanced the PI3K/AKT/mTOR pathway, resulting in increased expression of c-myc, ultimately promoting BC occurrence and progression. These results indicate that STIL might be a potential target for BC patients.

27 January 2025 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
XZXinye Zhang
Xinye Zhang
LZLu Zhang
Lu Zhang
LZLinfang Zhou
Linfang Zhou
HTHuangheng Tao
Huangheng Tao
ZCZhi Chen
Zhi Chen

4 August 2025 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
XZXinye Zhang
Xinye Zhang
LZLinfang Zhou
Linfang Zhou
CTCheng Tian
Cheng Tian
HTHuangheng Tao
Huangheng Tao
N6-methyladenosine (m6A), an abundant internal RNA modification in eukaryotes, serves as a dynamic post-transcriptional regulator of gene expression by influencing RNA splicing, stability, translation, and decay. This reversible epitranscriptomic mechanism, which is mediated by methyltransferase (writers), demethylase (erasers), and m6A-binding proteins (readers), is pivotal in diverse biological contexts. Among m6A erasers, alkylation repair homolog protein 5 (ALKBH5), an Fe(II)/α-ketoglutarate-dependent dioxygenase, is the second to be discovered and one of the most significant demethylases. Mounting evidence underscores ALKBH5’s role in modulating developmental programming, where it coordinates processes such as lineage specification, organogenesis, and tissue homeostasis. This review systematically deciphers the multifaceted contributions of ALKBH5-mediated m6A demethylation to developmental biology. We synthesize recent advances elucidating how ALKBH5-driven m6A erasure dynamically regulates transcriptomic rewiring during embryogenesis, reproductive development, cardiac development, central nervous system development, immune system development, pancreatic organogenesis, osteogenic/odontogenic differentiation, adipogenesis, and angiogenesis. These revelations not only deepen our understanding of epitranscriptomic regulation in ontogeny but also illuminate therapeutic avenues for developmental anomalies and regenerative medicine.

21 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
JPJiahao Peng
Jiahao Peng
CXChong Xie
Chong Xie
ZXZhangmin Xie
Zhangmin Xie
FTFeng Tang
Feng Tang
ZWZhiying Wang
Zhiying Wang
YLYixiang Liao
Yixiang Liao
Urological malignancies, including prostate, bladder, and renal cancers, remain a major clinical challenge because of tumor heterogeneity, disease progression, and therapeutic resistance. In this context, RNA methylation has emerged as an important post-transcriptional regulatory layer in cancer biology. Importantly, the biological consequences of RNA methylation are not dictated by chemical modifications alone, but by coordinated networks of regulatory proteins that install, remove, and interpret these marks, thereby shaping RNA fate and gene expression programs. Among currently studied RNA modifications, N 6 -methyladenosine (m 6 A) provides the most mature mechanistic framework, whereas non-m 6 A regulators remain comparatively less well characterized. In this review, we systematically summarize the regulatory logic underlying RNA methylation-mediated control in urological cancers, with particular emphasis on how distinct classes of regulatory proteins influence RNA stability, translation, metabolism, and other post-transcriptional processes. We further integrate current evidence across multiple RNA methylation types, including m 6 A, 5-methylcytosine (m 5 C), N 1 -methyladenosine (m 1 A), and N 7 -methylguanosine (m 7 G), while highlighting the relative immaturity of non-m 6 A evidence in these malignancies. We also provide an overview of current m 6 A detection technologies and discuss their methodological strengths, limitations, and appropriate research applications. Beyond mechanistic insights, we discuss the emerging clinical relevance of RNA methylation regulators in urological malignancies, particularly in relation to diagnostic-related evidence, prognostic stratification, immune-related relevance, and treatment-associated adaptation. In addition, we summarize current therapeutic efforts targeting RNA methylation pathways, including small-molecule inhibitors and related translational strategies, while emphasizing their present limitations. Overall, current evidence supports RNA methylation as a biologically important and increasingly translationally relevant framework in urological cancers, but not yet as a clinically mature one.